Drug intelligence / Profile preview

2-(3-benzoylphenoxy)ethyl(hydroxy)formamide

Development stage: Preclinical
Modality: Small Molecules

Overview

2-(3-benzoylphenoxy)ethyl(hydroxy)formamide is a synthetic small molecule belonging to the benzophenone class of organic compounds. It has been investigated as an experimental agent and is primarily known as a peptide deformylase inhibitor. Peptide deformylase is an enzyme involved in bacterial protein maturation by removing the formyl group from nascent proteins; thus, inhibitors of this enzyme are explored for their potential antibacterial activity. The compound has not been approved for any clinical use and remains at the discovery or investigative stage[1][3][5].

Other names: N-[2-(3-benzoylphenoxy)ethyl]-N-hydroxyformamideFormamide, N-[2-(3-benzoylphenoxy)ethyl]-N-hydroxy-DEF_ECOLIDEF_HAEINDEF_STAAMDEF_STRR6

Targets

PDF (Peptide deformylase, mitochondrial)

Beyond the preview

Go deeper on 2-(3-benzoylphenoxy)ethyl(hydroxy)formamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-(3-benzoylphenoxy)ethyl(hydroxy)formamide.

Explore the full profile